Clinical Trials Browser

INDUSTRY × Interventional × Antibodies × Clear all

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT07008703 2025-06-06

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Phase 1/2 Recruiting

Cancer Pain

NCT06451497 2024-12-04

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT05259397 2023-03-08

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Withdrawn

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02410512 2022-04-01

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Neoplasms

NCT02367794 2022-03-21

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Phase 3 Completed

1,021 enrolled 33 charts

Squamous Non-Small Cell Lung Cancer

NCT02458638 2021-06-04

A Study of Atezolizumab in Advanced Solid Tumors

Phase 2 Completed

474 enrolled 14 charts

Neoplasms

NCT01765790 2021-05-05

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms